CA2822288A1 - Fragments et anticorps anti-c5/c5a/c5adesr - Google Patents

Fragments et anticorps anti-c5/c5a/c5adesr Download PDF

Info

Publication number
CA2822288A1
CA2822288A1 CA2822288A CA2822288A CA2822288A1 CA 2822288 A1 CA2822288 A1 CA 2822288A1 CA 2822288 A CA2822288 A CA 2822288A CA 2822288 A CA2822288 A CA 2822288A CA 2822288 A1 CA2822288 A1 CA 2822288A1
Authority
CA
Canada
Prior art keywords
antibody
antigen
amino acid
c5adesr
binding fragment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2822288A
Other languages
English (en)
Inventor
Caroline COLLEY
Claire Dobson
Joanne BRENNAN
Sek Fung
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
MedImmune LLC
Original Assignee
MedImmune LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by MedImmune LLC filed Critical MedImmune LLC
Publication of CA2822288A1 publication Critical patent/CA2822288A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
CA2822288A 2010-12-22 2011-12-21 Fragments et anticorps anti-c5/c5a/c5adesr Abandoned CA2822288A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201061426021P 2010-12-22 2010-12-22
US61/426,021 2010-12-22
PCT/US2011/066437 WO2012088247A2 (fr) 2010-12-22 2011-12-21 Fragments et anticorps anti-c5/c5a/c5adesr

Publications (1)

Publication Number Publication Date
CA2822288A1 true CA2822288A1 (fr) 2012-06-28

Family

ID=46314882

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2822288A Abandoned CA2822288A1 (fr) 2010-12-22 2011-12-21 Fragments et anticorps anti-c5/c5a/c5adesr

Country Status (2)

Country Link
CA (1) CA2822288A1 (fr)
WO (1) WO2012088247A2 (fr)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113166236A (zh) * 2018-09-21 2021-07-23 北卡罗来纳大学查佩尔希尔分校 限制穿过黏液的合成粘合剂
CN113416254A (zh) * 2014-03-07 2021-09-21 瑞颂医药公司 具有改善的药物动力学的抗c5抗体
CN114149501A (zh) * 2020-12-11 2022-03-08 天士力生物医药股份有限公司 抗c5抗体及其应用

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2568436T3 (es) 2006-03-31 2016-04-29 Chugai Seiyaku Kabushiki Kaisha Procedimiento para controlar la farmacocinética en sangre de anticuerpos
EP3689912A1 (fr) 2007-09-26 2020-08-05 Chugai Seiyaku Kabushiki Kaisha Procédé de modification d'un anticorps par point isoélectrique par substitution d'acide aminé dans cdr
EP4238993A3 (fr) 2008-04-11 2023-11-29 Chugai Seiyaku Kabushiki Kaisha Molécule de liaison à l'antigène capable de se lier à deux ou plusieurs molécules d'antigène de manière répétée
SG190727A1 (en) 2010-11-30 2013-07-31 Chugai Pharmaceutical Co Ltd Antigen-binding molecule capable of binding to plurality of antigen molecules repeatedly
DK3798230T3 (en) * 2011-06-06 2022-10-31 Novo Nordisk As Terapeutiske antistoffer
US20160271216A1 (en) * 2013-08-09 2016-09-22 Apellis Pharmaceuticals, Inc. Compositions and methods relating to c5l2
BR112016015589A2 (pt) * 2014-01-06 2017-10-31 Hoffmann La Roche módulos de trânsito monovalentes para a barreira hematoencefálica
SG11201607165YA (en) 2014-12-19 2016-09-29 Chugai Pharmaceutical Co Ltd Anti-c5 antibodies and methods of use
EP3494991A4 (fr) 2016-08-05 2020-07-29 Chugai Seiyaku Kabushiki Kaisha Composition pour la prophylaxie ou le traitement de maladies liées à il-8
EP3529619B1 (fr) * 2016-10-19 2021-06-30 Alexion Pharmaceuticals, Inc. Procédé de quantification de c5a non lié dans un échantillon
EP3529618B1 (fr) * 2016-10-19 2020-12-02 Alexion Pharmaceuticals, Inc. Procédé de quantification de c5 non liée dans un échantillon
CA3057146A1 (fr) * 2017-03-23 2018-09-27 The Trustees Of The University Of Pennsylvania Anticorps anti-c5a et utilisations de ceux-ci
US11472889B2 (en) 2017-10-14 2022-10-18 Cytomx Therapeutics, Inc. Antibodies, activatable antibodies, bispecific antibodies, and bispecific activatable antibodies and methods of use thereof
EP4172200A1 (fr) * 2020-06-24 2023-05-03 Staidson (Beijing) Biopharmaceuticals Co., Ltd. Anticorps reconnaissant de manière spécifique c5a et leurs utilisations
CN116670288A (zh) * 2021-12-22 2023-08-29 舒泰神（北京）生物制药股份有限公司 一种分离的抗C5a抗体及其制剂与应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ520392A (en) * 2000-02-10 2005-04-29 Abbott Lab Antibodies that bind human interleukin-18 and methods of making and using
US20040191260A1 (en) * 2003-03-26 2004-09-30 Technion Research & Development Foundation Ltd. Compositions capable of specifically binding particular human antigen presenting molecule/pathogen-derived antigen complexes and uses thereof
US7084257B2 (en) * 2001-10-05 2006-08-01 Amgen Inc. Fully human antibody Fab fragments with human interferon-gamma neutralizing activity
WO2006124269A2 (fr) * 2005-05-16 2006-11-23 Amgen Fremont Inc. Anticorps monoclonaux humains se fixant a l'antigene-1 tres tardif pour le traitement de l'inflammation ainsi que d'autres troubles
KR20210044318A (ko) * 2006-06-06 2021-04-22 얀센 백신스 앤드 프리벤션 비.브이. 장내구균에 대한 사멸활성을 갖는 인간결합분자 및 그것의 용도
US20090304590A1 (en) * 2007-05-29 2009-12-10 Wyeth Therapeutic compositions and methods
CN102027002A (zh) * 2008-05-16 2011-04-20 三星电子株式会社 用于纯化蛋白质的方法和亲和柱
PL2328616T3 (pl) * 2008-08-05 2015-10-30 Novartis Ag Kompozycje i sposoby dla przeciwciał celujących białko dopełniacza C5

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113416254A (zh) * 2014-03-07 2021-09-21 瑞颂医药公司 具有改善的药物动力学的抗c5抗体
CN113166236A (zh) * 2018-09-21 2021-07-23 北卡罗来纳大学查佩尔希尔分校 限制穿过黏液的合成粘合剂
CN114149501A (zh) * 2020-12-11 2022-03-08 天士力生物医药股份有限公司 抗c5抗体及其应用
CN114149501B (zh) * 2020-12-11 2023-05-26 天士力生物医药股份有限公司 抗c5抗体及其应用

Also Published As

Publication number Publication date
WO2012088247A2 (fr) 2012-06-28
WO2012088247A3 (fr) 2012-09-20

Similar Documents

Publication Publication Date Title
CA2822288A1 (fr) Fragments et anticorps anti-c5/c5a/c5adesr
TWI796328B (zh) Ｂ７-ｈ３抗體、其抗原結合片段及其醫藥用途
TWI564305B (zh) 治療性抗體
EP2797952B1 (fr) Procédé de fourniture d'auto-anticorps monoclonaux avec une spécificité désirée
KR20210099052A (ko) 항-pd-l1/항-4-1bb 이중특이적 항체 및 이의 용도
JP7179743B2 (ja) 抗ＳＩＲＰｇ抗体の新規の使用
US11814426B2 (en) Anti-tenascin C antibodies and uses thereof
KR20170132811A (ko) 신규한 il33 형태, il33의 돌연변이된 형태, 항체, 검정 및 이의 이용 방법
AU2013370009B2 (en) Anti-granulysin antibodies and methods of use thereof
CA2977621C (fr) Nouvel anticorps se liant a la tfpi et composition le comprenant
KR101504039B1 (ko) 인간 및 마우스 ｌ１ｃａｍ 단백질에 특이적으로 결합하는 항체 및 이의 용도
EP1871807A2 (fr) Anticorps contre cxcr4 et leurs procédés d'utilisation
KR20110082172A (ko) Ｉｌ-1ｒ1에 대한 결합 성분
KR20140003467A (ko) 항il-18 항체 및 그의 용도
EP2493930A1 (fr) Compositions et méthodes pour le traitement de troubles inflammatoires
JP2021529520A (ja) 抗ｓｉｒｐ−ベータ１抗体及びその使用方法
JP2021508498A (ja) 抗ｔｍｅｍ１０６ｂ抗体及びその使用方法
CN110790839A (zh) 抗pd-1抗体、其抗原结合片段及医药用途
CA3184987A1 (fr) Traitement de maladies inflammatoires faisant appel a des anticorps anti-facteur tissulaire
AU2013269652A1 (en) TLR3 binding agents
JP2022540859A (ja) 新規ｂｓｓｌ抗体
WO2020239014A1 (fr) Anticorps anti cgrp et son utilisation
WO2021011678A1 (fr) Anticorps anti-trem-1 et leurs utilisations
CN113056480A (zh) 人源化抗N截短淀粉样β单克隆抗体
US20220041706A1 (en) Anti-fgf19 antibodies

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20141223